Furthermore, since the safety profile of osimertinib was found to be better than those of other standard EGFR-TKIs in clinical trials [23,24], it is one of the promising drugs for the treatment of pancreatic cancer and glioblastoma. This evidence concerns the gene EGFR and pancreatic neoplasm.